Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027’ has studied the cardiac surgery devices market and expects it to record a CAGR of 3.7% and be worth over US$ 2 Bn by end 2027.
The perfusion disposables segment represents a considerably larger market opportunity than either catheters, beating heart surgery systems, or heart lung machines in the cardiac surgery devices market.
The perfusion disposables segment is predicted to be worth more than US$ 800 Mn in 2017 alone with oxygenators contributing the lion’s share of this.
By the end of the forecast period, the segment is on track to push past US$ 1.1 Bn, making it a particularly lucrative segment in the cardiac surgery devices market as its attractiveness index is 2.0.
A greater acceptance of heart lung machine tables is expected to benefit the adoption of perfusion disposables in the cardiac surgery devices market.
Nearly a third of all the global deaths can be attributed to cardiovascular diseases and it is the main cause of death in the U.S., responsible for 17% of national healthcare expenditure.
The American Heart Association estimates that 40% of the American people will suffer from cardiovascular ailments in 2030 and the direct cost of these would skyrocket to approx. US$ 820 Billion.
https://www.futuremarketinsights.com/reports/sample/rep-gb-4602
Well-developed Medical Infrastructure Makes North America Keep its Crown
North America has a world-class medical infrastructure coupled with a population that is rapidly ageing and suffering from cardiopulmonary disorders.
This combination all but ensures that the region is larger than both Western Europe and APEJ combined in the year 2017 with a value of just under US$ 555 Mn.
North America is on track to witness a CAGR of 4.1% for the period 2017-2027 that should see the market in the region touch US$ 830 Mn by end 2027.
Most new developments are centred in North America and its high acceptance of modern technology make it an extremely lucrative region in the global cardiac surgery devices market.
Minimally Invasive Surgery Gaining Traction in Cardiac Surgery Devices Market
Coronary artery bypass grafting is anticipated to be the largest contributor in the cardiac surgery devices market by procedure in 2017 and it is unlikely to cede this position anytime soon.
However, modern advancements in cardiopulmonary bypass techniques, surgical approaches and incisions have made minimally invasive surgery increasingly popular in recent times.
Minimally invasive surgery has the advantage of reduced surgical trauma and decreased pain and this is anticipated to propel the cardiac surgery devices market in the long term.
In terms of CAGR these two segments hold the top position in the global cardiac surgery devices market, with coronary artery bypass grafting recording a value CAGR of 3.5% and minimally invasive surgery registering a 4.1% CAGR in terms of revenue during the forecast period.
Focus on Hospitals over Ambulatory Surgical Centres in the Cardiac Surgery Devices Market
The hospitals segment is larger than the ambulatory surgical centres segment by end user in the cardiac surgery devices market and this trend is predicted to continue for the foreseeable future.
An attractiveness index of 1.1 and a market opportunity of almost US$ 1.2 Bn by 2027 end should make all major companies actively target the hospitals end user segment in the cardiac surgery devices market.
The companies actively involved in the global cardiac surgery devices market that have been profiled in the report include Biotronik, Braile Biomedica, Cook Medical Inc., Estech, Abiomed, Smith Medical, MicroPort Scientific Corporation, Edwards Lifesciences Corporation, Angiodynamics, Teleflex Incorporated, C. R. Bard, Inc, B. Braun Melsungen AG, Getinge-Maquet Germany Holding GmbH, Terumo Corporation, LivaNova PLC, Lepu Medical technology Co ltd., Boston Scientific Corporation, Medtronic, and Abbott Laboratories.
Get In Touch With Our Team For 20% Flat Discount:
https://www.futuremarketinsights.com/ask-question/rep-gb-4602
The increasing preference for minimally invasive surgical procedures is one of the recent trends seen in the cardiac surgery devices market.
In the last decade, minimally invasive cardiothoracic surgery has grown by leaps and bounds mainly because of the reduced pain and surgical trauma after this procedure.
Even though coronary artery bypass grafting is much larger at present, key stakeholders are advised to focus on minimally invasive procedures as patients will almost certainly prefer this form of treatment.
In addition to this, the beating heart surgery system type could see widespread adoption in the days ahead.
Cardiac Surgery Devices Market Taxonomy
https://www.futuremarketinsights.com/customization-available/rep-gb-4602
ABOUT FUTURE MARKET INSIGHTS, INC.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2022 PHARMIWEB.COM LIMITED, rights reserved by the relevant holders.
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.